Loading stock data…
Adaptive Biotechnologies Corpor (ADPT)
$21.57+0.62 (+2.93%)
Market OpenUpdated 3:09 PM EDT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Adaptive Biotechnologies Corporation in the Healthcare sector is trading at $21.52 with a market capitalization of $2.4B. Wall Street consensus targets $20.29 (7 analysts), implying a -5.7% move over the next 12 months. The stock is currently near its 52-week high of $21.59, remaining 37.4% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -5.7% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $70.87M↓ | $71.68M↓ | $93.97M↑ | $58.88M↑ | $52.44M |
| Gross Profit | $52.17M↓ | $53.46M↓ | $75.82M↑ | $40.88M↑ | $35.46M |
| Operating Income | -$19.21M↓ | -$12.77M↓ | $10.29M↑ | -$25.04M↑ | -$29.60M |
| Net Income | -$20.03M↓ | -$13.58M↓ | $9.55M↑ | -$25.61M↑ | -$29.85M |
Peer Comparison
JNJUNHPFE
Fundamentals
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.42B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.16
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.96%
Volume
Today's trading volume
2.14M
Recent News
BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the Best Growth Stocks to Buy and Hold for the Next Decade. On June 17, BTIG maintained a Buy rating on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) with a $22 price target. The rating is based on two significant announcements from the company. Firstly, Adaptive announced an upsized convertible notes […]
Adaptive Biotechnologies plans separation of immune medicine platform
June 15 (Reuters) - Adaptive Biotechnologies said on Monday it planned to separate its immune medicine business from its residual cancer-testing unit, as it reviews options for the drug-discovery
What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?
Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong year-over-year share gains.
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
Adaptive Biotechnologies (ADPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
How The Adaptive Biotechnologies (ADPT) Narrative Is Shifting Around A US$20 Fair Value Anchor
The latest update keeps Adaptive Biotechnologies’ fair value estimate anchored at US$20.14 per share, even as analysts refine the underlying assumptions. That price target reflects a blend of bullish and bearish views, with some analysts pointing to long term revenue potential and others focused on execution risk and the timing of profitability. As you read on, you will see how this evolving narrative might shape your view of the stock’s risk and reward profile. Wall Street's queuing for one...